Table 4

Genes that have a cohort-dependent association (P-value < 0.05) with the lifetime glioblastoma survival

Gene Symbol

Probe Identifier

Clinical Cohort

P-value

Level of Clinical Cohort

Hazard Ratio1

Relevant literature references


Prkcb2

207957_s_at

Gender

<.0001

Male

0.36 (0.24-0.55)

[28]G

Female

1.27 (0.84-1.93)

Therapy

0.0006

None

0.38 (0.25-0.60)

CRnoT

0.51 (0.36-0.73)

R

0.64 (0.46-0.88)

CRT

0.71 (0.44-1.13)

Other

0.75 (0.43-1.32)

Sox10

209843_s_at

Race

0.0018

White

0.55 (0.44-0.68)

[10]G

Other

1.08 (0.72-1.62)

Egfr

211607_x_at

Gender

<.0001

Male

0.60 (0.50-0.72)

[24]G

Female

0.88 (0.74-1.04)

Chi3l1

209396_s_at

Therapy

0.0006

CRT

1.27 (0.96-1.70)

[70]G

R

1.28 (1.07-1.52)

Other

1.31 (1.04-1.66)

CRnoT

1.53 (1.31-1.79)

None

2.42 (1.56-3.75)

C2

203052_at

Gender

0.0033

Female

1.30 (1.03-1.65)

n/a

Male

1.93 (1.56-2.39)

Prkcb

209685_s_at

Gender

<.0001

Female

1.31 (0.79-2.14)

[28]G

Male

5.21 (3.16-8.61)


n/a, No association with any type of cancer found in literature;

1 Hazard ratio estimate (95% confidence interval);

2 Interaction with a single clinical cohort factor;

G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;

O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.

SerĂ£o et al. BMC Medical Genomics 2011 4:49   doi:10.1186/1755-8794-4-49

Open Data